Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding
Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding supports healthcare professionals through independent education that strengthens their knowledge and skills to better meet patient and community needs.
Funder: Johnson & Johnson (Janssen)
Due Dates: Six weeks before program start (general submission requirement) | Approximately November 1, 2026 (anticipated ITCI portal availability, not a deadline)
Funding Amounts: No ITCI-specific award amount or range published; full or partial funding may be approved
Summary: ITCI Corporate Funding supports independent healthcare professional education to strengthen knowledge and skills for patient and community needs.
Key Information: Requests for 2026 events may be emailed during the portal transition; 2027 requests must await ITCI availability in CyberGrants.
Description
Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding is presented within Johnson & Johnson’s support for independent training and continuing medical education. This educational funding helps organizations strengthen the knowledge and skills of healthcare professionals, including physicians, nurses, residents, and pharmacists, so they can better meet patient and community needs.
The shared educational-grant priorities emphasize therapeutic areas of interest and initiatives serving communities facing barriers to equitable healthcare access and representation. Neuroscience, oncology, and immunology are identified as shared therapeutic interests, rather than a separate ITCI-specific scope. Requests undergo internal review under the company’s educational-grant guidelines. The broader educational-grant framework covers accredited and non-accredited professional education, patient education, fellowship programs, and fellowship travel support.
